Evidence map›Paper›PMID 26719843›Full record

ArticleOpen forum infectious diseases2015

Human Cytomegalovirus Up-Regulates Endothelin Receptor Type B: Implication for Vasculopathies?

Koon-Chu Yaiw, Abdul-Aleem Mohammad, Helena Costa, Chato Taher, Sigrun Badrnya, Alice Assinger, Vanessa Wilhelmi, Sharan Ananthaseshan, Atosa Estekizadeh, Belghis Davoudi and 8 more

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Endothelins in inflammatory neurological diseases.Pharmacology & therapeutics · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 3 countries.

Koon-Chu YaiwDepartment of Medicine, Solna, Center for Molecular Medicine, Microbial Pathogenesis Unit , Karolinska University Hospital, Karolinska Institutet.
Abdul-Aleem MohammadDepartment of Medicine, Solna, Center for Molecular Medicine, Microbial Pathogenesis Unit , Karolinska University Hospital, Karolinska Institutet.
Helena CostaDepartment of Medicine, Solna, Center for Molecular Medicine, Microbial Pathogenesis Unit , Karolinska University Hospital, Karolinska Institutet.
Chato TaherDepartment of Medicine, Solna, Center for Molecular Medicine, Microbial Pathogenesis Unit , Karolinska University Hospital, Karolinska Institutet.
Sigrun BadrnyaDepartment of Medicine, Solna, Center for Molecular Medicine, Microbial Pathogenesis Unit , Karolinska University Hospital, Karolinska Institutet ; Center for Physiology and Pharmacology , Institute of Physiology, Medical University of Vienna , Austria.
Alice AssingerDepartment of Medicine, Solna, Center for Molecular Medicine, Microbial Pathogenesis Unit , Karolinska University Hospital, Karolinska Institutet ; Center for Physiology and Pharmacology , Institute of Physiology, Medical University of Vienna , Austria.
Vanessa WilhelmiDepartment of Medicine, Solna, Center for Molecular Medicine, Microbial Pathogenesis Unit , Karolinska University Hospital, Karolinska Institutet.
Sharan AnanthaseshanDepartment of Medicine, Solna, Center for Molecular Medicine, Microbial Pathogenesis Unit , Karolinska University Hospital, Karolinska Institutet.
Atosa EstekizadehDepartment of Medicine, Solna, Center for Molecular Medicine, Microbial Pathogenesis Unit , Karolinska University Hospital, Karolinska Institutet.
Belghis DavoudiDepartment of Medicine, Solna, Center for Molecular Medicine, Microbial Pathogenesis Unit , Karolinska University Hospital, Karolinska Institutet.
Olga OvchinnikovaDepartment of Medicine, Solna, Center for Molecular Medicine, Microbial Pathogenesis Unit , Karolinska University Hospital, Karolinska Institutet.
Eugene ShlyakhtoAlmazov Federal Heart, Blood and Endocrinology Centre , St . Petersburg , Russia.
Arnar RafnssonDepartment of Medicine, Solna, Center for Molecular Medicine, Microbial Pathogenesis Unit , Karolinska University Hospital, Karolinska Institutet ; Department of Medicine, Cardiology Unit , Karolinska University Hospital Solna , Stockholm , Sweden.
Zahidul KhanDepartment of Medicine, Solna, Center for Molecular Medicine, Microbial Pathogenesis Unit , Karolinska University Hospital, Karolinska Institutet.
Lynn ButlerDepartment of Medicine, Solna, Center for Molecular Medicine, Microbial Pathogenesis Unit , Karolinska University Hospital, Karolinska Institutet.
Afsar RahbarDepartment of Medicine, Solna, Center for Molecular Medicine, Microbial Pathogenesis Unit , Karolinska University Hospital, Karolinska Institutet.
John PernowDepartment of Medicine, Solna, Center for Molecular Medicine, Microbial Pathogenesis Unit , Karolinska University Hospital, Karolinska Institutet ; Department of Medicine, Cardiology Unit , Karolinska University Hospital Solna , Stockholm , Sweden.
Cecilia Söderberg-NauclérDepartment of Medicine, Solna, Center for Molecular Medicine, Microbial Pathogenesis Unit , Karolinska University Hospital, Karolinska Institutet.
Karolinska University Hospital · SEKarolinska Institutet · SEFederal Almazov North-West Medical Research Centre · RUMedical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background.  Both endothelin receptor type B ([ETBR], a G protein-coupled receptor that mediates the vascular effects of the potent vasoconstrictor endothelin-1) and human cytomegalovirus ([HCMV], a ubiquitous herpesvirus) have been implicated in the pathogenesis of cardiovascular disease (CVD). The effects of HCMV infection on ETBR expression are unknown. We hypothesized that HCMV may contribute to the pathogenesis of CVD via ETBR modulation. Methods.  Human CMV effects on ETBR were studied in vitro in endothelial cells (ECs) and smooth muscle cells (SMCs) and ex vivo in human carotid plaque tissue specimens. Expression of ETBR and viral immediate-early were quantified using quantitative polymerase chain reaction. Functional consequences after ETBR blockade in ECs were examined by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide proliferation, wound healing, tube formation, and flow adhesion assays. Results.  Human CMV is capable of upregulating both ETBR mRNA and protein expression in ECs and SMCs. The ETBR was also abundantly expressed in ECs, foam cells, and SMCs, and, more importantly, in HCMV-positive cells in human carotid plaques. Endothelin receptor type B blockade led to decreased proliferation and reduced tumor necrosis factor α-mediated leukocyte recruitment in both uninfected and HCMV-infected ECs. Direct HCMV infection was antimigratory and antiangiogenic in ECs. Conclusions.  Human CMV may contribute to CVD via ETBR induction.

Indexed as

angiogenesisBQ788cytomegalovirusendothelial cellsendothelin receptor type Bleukocyte recruitmentvasculopathies

Identifiers

PMID26719843
PMCPMC4690546
OpenAlexW2228518579

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.